Biomea Fusion BMEA 深 沪
交易中 09-18 10:33:32 美东时间
1.99
+0.030
+1.53%
华盛通- 最 高2.05
- 今 开2.02
- 成交量 20.23万股
- 最 低 1.99
- 昨 收 1.96
- 总市值 1.13亿
- 52周最高 13.07
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.2905
- 委 比 46.73%
- 总股本 5702.23万
- 历史最高 43.69
- 量 比 2.14
- 振 幅 3.06%
- 历史最低 1.2905
- 每 手 1
- 风险率 3.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update
Biomea Fusion announced positive preclinical results for icovamenib, a menin inhibitor, combined with low-dose semaglutide in a T2D rodent model. The combination improved glycemic control, reduced body weight without losing lean mass, and showed better outcomes than semaglutide alone. Additionally, the FDA cleared the IND for BMF-650, an oral GLP-1 RA, with Phase I obesity trials expected to begin soon. Results highlight icovamenib's potential to...
09-16 11:00
Jefferies Initiates Coverage On Biomea Fusion with Buy Rating, Announces Price Target of $5
Jefferies analyst Roger Song initiates coverage on Biomea Fusion (NASDAQ:BMEA) with a Buy rating and announces Price Target of $5.
08-28 20:31
美股大行评级 | Rivian遭多家大行下调目标价；巴克莱上调超微公司目标价从130美元升至200美元
今日重点评级关注：韦德布什：维持Gossamer Bio"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持EyePoint Pharmaceuticals"买入"评级，目标价从22美元升至23美元
08-07 09:46
Scotiabank Maintains Sector Outperform on Biomea Fusion, Lowers Price Target to $10
Scotiabank analyst George Farmer maintains Biomea Fusion (NASDAQ:BMEA) with a Sector Outperform and lowers the price target from $30 to $10.
08-07 00:27
Biomea Fusion Q2 EPS $(0.51) Beats $(0.54) Estimate
Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.54) by 5.73 percent. This is a 50.49 percent increase over losses of $(1.03) per share from the
08-06 04:36
Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights
Biomea Fusion reported positive results for icovamenib in treating type 2 diabetes and obesity, showing improved glycemic control and weight loss. BMF-650, a next-gen GLP-1 RA, demonstrated significant weight reduction in primates. The company raised $42.8M, reducing operational expenses to extend cash runway into 2026. Key milestones include IND submission for BMF-650 and advancing icovamenib trials.
08-05 20:05
Biomea Fusion Appoints Julianne Averill to its Board of Directors
Biomea Fusion, Inc. has appointed Julianne Averill to its Board of Directors and the Audit Committee, effective July 22, 2025, succeeding Bihua Chen. Averill, a seasoned finance and strategy executive, brings over two decades of experience in life sciences and digital health. She currently serves as Managing Director at Danforth Advisors and specializes in capital markets, M&A, and organizational design. Averill holds an M.S. in Accountancy and i...
07-24 11:00
美股大行评级 | 潜在涨幅23.77%！美国运通获德银升目标价至375美元，维持"买入"评级
今日重点评级关注：德银：维持美国运通"买入"评级，目标价从371美元升至375美元；巴克莱：维持Gaming and Leisure Props"标配"评级，目标价从54美元升至55美元
07-22 09:35
Citigroup Maintains Buy on Biomea Fusion, Lowers Price Target to $9
Citigroup analyst Yigal Nochomovitz maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and lowers the price target from $22 to $9.
07-16 22:44
Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)
Biomea Fusion announced new data on icovamenib, an oral menin inhibitor, at ADA 2025. Preclinical studies show icovamenib enhances glycemic control and weight loss when combined with low-dose semaglutide, while preserving lean mass. It also rescues human myotube atrophy ex vivo. In the Phase II COVALENT-111 trial, icovamenib achieved a 1.0% placebo-adjusted HbA1c reduction and a 55% increase in C-peptide at Week 26, demonstrating durable effects ...
06-23 11:00
